Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (AVHHL) Common Equity (2019 - 2025)

Historic Common Equity for AVITA Medical (AVHHL) over the last 7 years, with Q4 2025 value amounting to -$16.6 million.

  • AVITA Medical's Common Equity fell 47008.22% to -$16.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$16.6 million, marking a year-over-year decrease of 47008.22%. This contributed to the annual value of -$16.6 million for FY2025, which is 47008.22% down from last year.
  • According to the latest figures from Q4 2025, AVITA Medical's Common Equity is -$16.6 million, which was down 47008.22% from -$6.7 million recorded in Q3 2025.
  • Over the past 5 years, AVITA Medical's Common Equity peaked at $118.9 million during Q1 2021, and registered a low of -$16.6 million during Q4 2025.
  • Moreover, its 5-year median value for Common Equity was $65.8 million (2023), whereas its average is $55.2 million.
  • Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 7555.25% in 2021, then tumbled by 47008.22% in 2025.
  • AVITA Medical's Common Equity (Quarter) stood at $104.6 million in 2021, then fell by 19.01% to $84.7 million in 2022, then crashed by 42.11% to $49.1 million in 2023, then crashed by 90.83% to $4.5 million in 2024, then tumbled by 470.08% to -$16.6 million in 2025.
  • Its Common Equity stands at -$16.6 million for Q4 2025, versus -$6.7 million for Q3 2025 and -$12.9 million for Q2 2025.